Rachel Roberts
Project Manager, Multi-Stage Malaria Vaccine Consortium (MMVC)
Recent publications
-
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Journal article
Datoo MS. et al, (2024), Lancet (London, England), 403, 533 - 544
-
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial.
Journal article
Datoo MS. et al, (2022), The Lancet. Infectious diseases, 22, 1728 - 1736
-
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial
Journal article
Datoo MS. et al, (2021), The Lancet, 397, 1809 - 1818
-
Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies
Journal article
Folegatti PM. et al, (2021), Vaccines, 9, 262 - 262
-
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.
Journal article
Folegatti PM. et al, (2020), The Lancet. Infectious diseases, 20, 816 - 826